Emergent Biosolutions (NYSE:EBS) Releases Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Emergent Biosolutions beat EPS expectations, reporting a quarterly loss of $0.36 per share versus the $0.39 consensus estimate, but revenue of $110 million fell short of the $123.22 million forecast and declined from $231 million a year earlier.
• The company cut full-year 2026 revenue guidance to $600 million–$645 million because of delayed medical-countermeasure deliveries and continued commercial pressure, while its shares fell 5.7% to $6.42.
• Emergent reported $122 million in year-to-date operating cash flow, $226 million in liquidity and $75 million in debt repurchases; restructuring is expected to generate about $40 million in annual savings, and analysts maintain a consensus “Hold” rating with a $10 average price target.

Emergent Biosolutions (NYSE:EBS - Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03, FiscalAI reports. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. The business had revenue of $110.00 million during the quarter, compared to the consensus estimate of $123.22 million.

Here are the key takeaways from Emergent Biosolutions' conference call:

• Full-year 2026 revenue guidance was reduced to $600 million–$645 million, reflecting lower expected MCM revenue as some U.S. government and international deliveries may shift into early 2027; commercial revenue is tracking toward the low end of the expected 20%–25% decline versus 2025.
• The company generated $122 million in year-to-date operating cash flow, ended the quarter with $226 million in liquidity, and reduced gross debt to $514 million after repurchasing $75 million of bond principal.
• Emergent expects restructuring actions to deliver approximately $40 million in annualized savings, with initial benefits beginning in the fourth quarter, and raised adjusted gross-margin guidance to 45%–47% due to operational improvements, product mix, and more stable NARCAN pricing.
• Third-quarter revenue fell to $110 million from $231 million a year earlier, while adjusted EBITDA was negative $5 million, pressured by MCM delivery timing, product mix, and competitive pricing and volume pressure in the naloxone market.
• Emergent said NARCAN remains the U.S. market leader despite new competitors, while international MCM activity reached 13 countries and contributed 22% of year-to-date MCM revenue; the company is also advancing pan-Ebola, pan-flu, AI-enabled development, and other growth programs.

Emergent Biosolutions Trading Down 5.7%

Shares of EBS traded down $0.39 during trading hours on Monday, hitting $6.42. 944,168 shares of the stock traded hands, compared to its average volume of 970,465. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70. Emergent Biosolutions has a 1-year low of $4.36 and a 1-year high of $14.06. The firm has a market capitalization of $329.36 million, a PE ratio of -1.81 and a beta of 2.37. The business has a fifty day moving average of $6.47 and a 200-day moving average of $8.05.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Emergent Biosolutions in a research note on Friday, August 21st. They issued an "underweight" rating for the company. Weiss Ratings upgraded shares of Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday, August 21st. Zacks Research raised shares of Emergent Biosolutions to a "hold" rating in a report on Tuesday, August 11th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Emergent Biosolutions currently has a consensus rating of "Hold" and an average price target of $10.00.

Insider Buying and Selling

In other Emergent Biosolutions news, Director Donald Degolyer sold 17,800 shares of the business's stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total transaction of $126,202.00. Following the completion of the sale, the director directly owned 111,921 shares of the company's stock, valued at approximately $793,519.89. The trade was a 13.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by insiders.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.